Kornimate/medical-research-clean huggingface dataset:
study to image the esophagus using the ofdi capsule

Conditions: Barrett's Esophagus; Eosinophilic Esophagitis

Summary: the main purpose of this research is to test the feasibility and tolerability of the tethered capsule optical frequency domain imaging (ofdi)

a total of 56 subjects with barrett's esophagus, eoe and healthy volunteers will be asked to swallow the ofdi capsule while being unsedated. the capsule is attached to a tether that allows the capsule operator to navigate the capsule as it progresses down the esophagus using natural propulsion called peristalsis as well as to bring it back up to pulled out of the mouth when the procedure is done. as the capsule progresses down the esophagus, multiple, two dimensional, microscopic cross- sectional images of the esophagus are acquired.

Eligibility criteria:
inclusion criteria: * a previous diagnosis of barrett's esophagus * or a previous diagnosis of eoe * or a previous diagnosis of gastroesophageal reflux disease (gerd) * subject must be 18 years or older in case of barrett's and gerd, and over the age of 16 years for eoe * subject must be able to give informed consent exclusion criteria: * subjects with known esophageal strictures, intestinal strictures or dysphagia * or subjects with a history of prior gi surgery or gi intestinal crohn's disease

Keywords: optical coherence tomography barrett's esophagus esophagus imaging
linkage study of long qt syndrome in an amish kindred

Conditions: Heart Diseases; Cardiovascular Diseases; Tachycardia, Ventricular; Ventricular Fibrillation; Long QT Syndrome

Summary: to screen by electrocardiography the entire population of 1,400 individuals in seven amish mennonite communities in order to perform genetic linkage studies of long qt syndrome (lqts).

background: lqts is a severe heart disorder leading to sudden death due to ventricular tachycardia or ventricular fibrillation. the syndrome segregated as a mendelian recessive in the highly inbred population under study and resulted in the sudden death of several members of the population. design narrative: the entire population was screened to identify cases of lqts. in addition, 29 obligate heterozygotes were studied by 24-hour holter monitoring to determine whether these gene carriers had any subtle phenotypes. the data were subjected to complex segregation and linkage analysis to establish the mode of inheritance and penetrance of lqts. the study completion date listed in this record was obtained from the "end date" entered in the protocol registration and results system (prs) record.

Eligibility criteria:
no eligibility criteria
effects of different doses of aspirin on pathophysiological markers in type 2 diabetes

Conditions: Diabetes Type 2

Summary: this study was set up to assess the effects of different doses of aspirin when compared with placebo (dummy drug), used sequentially over a 2 week study period with a 2 week wash-out (rest period) in between, in people with type-2 diabetes and high cardiovascular risk. specifically, its effects on different factors which are thought to contribute to diabetes such as insulin resistance (body's ability to effectively use insulin), dysglycaemia (excess glucose in the blood), oxidative stress (effects from accumulation of by-products of metabolism), endothelial function (function of lining of blood vessels) and inflammation were studied.


Eligibility criteria:
inclusion criteria: * diabetes type 2 * age \> 18 and \< 70 * high cardiovascular risk exclusion criteria: * presence of active/established cardiovascular disease (ischaemic heart disease, cerebrovascular disease or peripheral vascular disease) * insulin treatment * patients with known peptic ulcer disease or those on anti-coagulation * significant renal impairment * aspirin intolerance * use of anticoagulants * significant liver disease

Keywords: diabetes aspirin oxidative stress insulin resistance endothelial function inflammation photoplethysmography dysglycaemia
drug eluting stent (des) in primary angioplasty

Conditions: Acute Myocardial Infarction

Summary: stent implantation is the best treatment in patients with acute myocardial infarction (stemi) referred for primary angioplasty (ppci). however the occurrence of in stent restenosis is responsible for the need of repeat intervention. both sirolimus-eluting stents (ses) and paclitaxel-eluting stents (pes) have been proven to virtually abolish in-stent restenosis in elective patients in simple e more complex lesions. both ses and pes have raised concerns regarding occurrence of late stent thrombosis, especially in complex lesion subsets or in high risk patients. the paclitaxel or sirolimus-eluting stent vs bare metal stent in primary angioplasty (paseo) trial was a prospective, single-center, randomized trial evaluating the benefits of ses or pes as compared to bms implantation in patients undergoing primary angioplasty for acute stemi. from 1 october 2003 we randomized with 1:1:1 ratio, 270 patients with stemi and treated with ppci, to implantation of a bare metal stent (bms n=90), pes (n=90) or ses (n=90).


Eligibility criteria:
inclusion criteria: * clinical symptoms of stemi, with initial onset of chest pain within the past 12 hours, an ecg demonstrating \> 0.1 mv st-segment elevation in 2 or more contiguous leads or documented new left bundle-branch block and were suitable candidates for percutaneous revascularization. exclusion criteria: * active internal bleeding or a history of bleeding diathesis within the previous 30 days * an history of intracranial hemorrhage * intracranial neoplasm * arteriovenous malformation or aneurysm * known allergy to sirolimus * paclitaxel * heparin, aspirin, or clopidogrel * an history of stroke within 30 days or any history of hemorrhagic stroke * history, symptoms, or findings suggestive of aortic dissection, fibrinolytic therapy within 24 hours * history of thrombocytopenia, pregnancy, patients on warfarin or acenocoumarol within the last seven days * inability to obtain the informed consent

Keywords: acute myocardial infarction drug eluting stent primary pci
effect of daily remote ischemic conditioning on the life quality of refractory angina pectoris patients

Conditions: Refractory Angina Pectoris

Summary: the purpose is to test whether daily ischemic conditioning of the arms over 30 days could reduce the frequency and severity of angina pectoris and improve the life quality of refractory angina pectoris patients.

refractory angina pectoris denotes "chronic stable angina that persists despite optimal medication and when revascularisation is unfeasible or where the risks are unjustified". these patients could potentially be relieved by non-conventional treatments like remote ischemic conditioning, and actually this effect has been observed in several cases in the center of the sponsor. this study is a pilot study to measure the efficacy and safety of this method in this group of patients.

Eligibility criteria:
inclusion criteria: * diagnosed angina pectoris that remains despite optimal medical treatment; * no chance of further revascularization or refusal to do revascularization; * the frequency and canadian cardiovascular society (ccs) scale stays stable over the past 3 months before inclusion. exclusion criteria: * known or highly suspected abnormality of peripheral arteries, veins, or extremities; * infection or fever in the past month; * blood pressure over 180/110 millimeters of mercury (mmhg) or below 80/50mmhg; * refusal to comply with the study protocol; * currently under sulfonylureas or prostaglandins therapy; * other conditions that the researchers judge as inappropriate to participate.

Keywords: refractory angina pectoris remote ischemic conditioning life quality anxiety depression inflammation
the shared, project, lung cancer screening for african american men (aam)

Conditions: Lung Cancer Screening

Summary: this study is a single-arm pre-test post-test design with a two-month follow-up assessment. the study aims to provide support to participants in quitting smoking and accessing lung cancer screening through the combination of education interventions and patient navigation (pn)

this study is a single-arm pre-test post-test design with a two-month follow-up assessment. the study aims to provide support to participants in quitting smoking and accessing lung cancer screening through the combination of education interventions and patient navigation (pn). after participant consent the study team will administer a series of surveys to collect the participant's contact information and complete the study's pretest measures. these include a demographic survey, smoking history, lung cancer knowledge, lung screening knowledge, intention to quit/screen, informed to decide, satisfaction survey, and decision conflict survey. the study also consists of three scheduled meetings with the pn lasting up to 60 minutes. the 1st session will be held between 7-14 days after consent. the 2nd session will be held 7-14 after the 1st session and the 3rd session will be held 42-49 days after the 1st session. additional phone calls will last 10 minutes or less and be focused on specific questions generated by study participants. in the 1st session the pn will re-orient participant to the goals and objectives of the project and answer participant questions before starting the intervention. the 1st activity will be to show a 3 minute culturally tailored video that will explain the benefits of lung cancer screening for african american males (aam) using an internet-enabled device. after completion of the video, the pn will invite the participant to ask any questions that they have and the pn will offer clarifying information. the pn will review with the participant a culturally adapted shared decision-making tool. the participant will complete the posttest surveys as described abov. in the 2nd session the pn will determine the scheduling and completion of lung cancer screening and illinois tobacco quit line (itql) engagement. the participant will complete the ldct screening, navigation needs, quitline engagement, and decision change surveys in the 3rd session the pn will determine scheduling, barriers and completion of lung cancer screening and quitline engagement. the participant will complete ldct screening check, and a quitline engagement check

Eligibility criteria:
inclusion criteria: 1. self-identify as african american or black males 2. current smokers of any nicotine-containing products 3. do not self-report a history of lung cancer symptoms 4. speaks english exclusion criteria: 1. do not self-identify as african american males 2. former smokers 3. self-report a history of lung cancer symptoms 4. do not speak english
cognitive function and emotional possessing in bilateral facial palsy

Conditions: Intelligence; Emotion

Summary: based on recent findings that botulinum toxin injections in the cranial muscles might reduce emotional processing (havas 2011), an increasing number of popular newspaper tabloids are suggesting a negative effect on cognition. the underlying research articles address the "facial feedback hypothesis". the hypothesis indicates that expressive behaviour, including facial mimic expressions influences the subject's brain via feedback. (alam 2008) other systemic neurological diseases, e.g of inflammatory origin, may lead to temporary bilateral facial nerve palsy (bf). during recovery process, the palsy usually remits completely. the effect of bilateral facial muscle palsy on cognition and emotional possessing has never been evaluated. the results of this pilot study might provide new information about the effect bilateral facial palsy on emotional processing and cognition and the facial feedback hypothesis. the aim of this controlled pilot study is to assess cognitive function and emotional processing in patients with bilateral facial palsy. in addition, differences in cognitive function and emotional processing in patients with different manifestations of dystonia should be evaluated. according to the facial feedback theory, paralysed mimic muscles might alter emotional processing. therefore, investigators compare patients with bilateral facial muscle palsy and healthy controls. investigators expect no influence of facial muscle palsy on cognitive functions in any of the tested groups; the investigators expect a mild impairment of emotional processing only in the patients group with bilateral facial muscle palsy (beb and bf). in addition, the investigators expect no difference in emotional processing in patients with different manifestations of dystonia (beb and cd) at remission. there might be a slight difference of emotional processing in patients with different manifestations of dystonia (beb and cd) at time of prominent facial palsy.


Eligibility criteria:
inclusion criteria: patients: * willing to participate in this pilot trial * bilateral facial palsy * age 18-80 years control: * willing to participate in this pilot trial * age, * gender and * education (duration of school attendance) matched * and/or cervical dystonia exclusion criteria: * neurological or psychiatric comorbidity * psychotropic drugs
occyo tele-ophthalmology study

Conditions: Cataract

Summary: the prospective, (observer) blinded clinical trial at the university hospital for ophthalmology includes patients routinely scheduled for cataract surgery at the medical university of innsbruck. patients are enrolled one week prior to their planned cataract surgery. the participants will undergo a screening in which, in addition to the ophthalmological standard examinations, occyo one images of the anterior segment of the eye are taken. after surgery, a post-operative follow-up visit takes place and a second set of occyo one images will be generated. during the postoperative check-up, the study team at the trial center decides-based on defined criteria (medical history, slit lamp examination results)-whether a change in the subsequent patient management is necessary due to the presence of postoperative complications (unexpected management changes = umc). up on completion of all patient visits/study-specific measurements and data collection, information regarding diagnostic criteria and the occyo one images are sent to an external, blinded ophthalmologist for telemedical assessment. based on the available information and images, the blinded ophthalmologist decides whether a change in patient management should have been made or not. the difference in the detection of an event resulting in a umc is the primary objective of this clinical investigation.


Eligibility criteria:
inclusion criteria: 1. understands and agrees to comply with the study procedures and provides written informed consent as documented by signature 2. patients scheduled to undergo cataract surgery 3. male or female patient aged ≥ 50 years at time of consent exclusion criteria: 1. woman of childbearing potential (wocbp)

Keywords: cataract slit lamp telemedical examination image based diagnosis
costimulatory molecules as biomarkers in cystic fibrosis

Conditions: Cystic Fibrosis

Summary: the purpose of this study is to investigate the expression of a certain class of molecules, called costimulatory molecules, in humans with cystic fibrosis. cystic fibrosis is a genetic disorder which renders the lung susceptible to persistent inflammation which, at times, can worsen, resulting in accelerated decline in lung function and eventually death or transplant. our goal is to determine if the levels of costimulatory markers can be used to predict exacerbation and subsequent lung function decline in subjects with cystic fibrosis.


Eligibility criteria:
inclusion criteria: * willingness to participate exclusion criteria: * presence of hiv * presence of lymphoma/leukemia * presence of lung or other solid organ transplant * pregnancy

Keywords: costimulatory molecules cystic fibrosis biomarkers
the effectiveness of carbonate apatite bone graft for alveolar ridge preservation

Conditions: Healing Wound

Summary: this study will examine whether the use of synthetic carbon apatite bone graft material will lead to more bone formation compared to human derived allograft and bovine derived xenograft material.

bone grafts are commonly placed to increase the amount of bone right after tooth extraction and prepare the site for future dental implant placement. 45 patients requiring a tooth extraction will be recruited and randomized to receive either allograft, xenograft, or synthetic bone grafting.

Eligibility criteria:
inclusion criteria: * age between 20 and 80 years old * patients requiring tooth extraction (incisors, canines, and premolars) due to caries, periodontal disease, tooth fracture, or unrestorable condition. * extraction sockets must be infection-free with dehiscence less than 5mm. * patients interested in implant placement after tooth extraction. exclusion criteria: * known allergies or hypersensitivities to medications related to the study (e.g., chlorhexidine) * hematologic disorders or blood dyscrasias. * active infectious diseases. * liver or kidney dysfunction/failure. * uncontrolled diabetes (i.e., hba1c \> 8). * undergoing active cancer treatment, including chemotherapy or radiotherapy within the last 12 months from the procedure. * use of medications affecting bone healing (e.g., bisphosphonates, long-term anti-inflammatory medications). * metabolic bone diseases affecting bone healing, such as osteoporosis (self-reported). * pregnant or lactating women (self-reported). * current smokers of 10 or more cigarettes per day and former smokers who quit less than 10 years ago (self-reported). * poor oral hygiene. * presence of fenestration defects equal to or greater than 5mm.
bioequivalence study of generic tretinoin 0.04% microsphere gel, 0.04% retin-a micro® and placebo

Conditions: Acne

Summary: the objective will be to assess clinical bioequivalence of 0.1% retin-a micro® gel and spear pharmaceutical's generic 0.1% tretinoin microsphere gel with a placebo arm.

acne study

Eligibility criteria:
a subject will be eligible to participate if they meet all of the following inclusion criteria: * normal, healthy male and female children and adults. * age 12 to 40 years. * written and verbal informed consent must be obtained. subjects age 12 to 17 (inclusive) must sign an assent for the study and a parent or a legal guardian must sign the informed consent (per fda letter 8.21.07). * women of child-bearing potential must be non-pregnant and non-nursing, and must be willing to avoid pregnancy during the course of the study and during the menstrual cycle following completion of their participation in the study, adequate contraception is defined as regular use of any two of the following: oral, injectable contraceptives, condoms, spermicides, diaphragm, iud, implantable and contraceptive patches. (oral contraceptives if used for at least three months and injectable contraceptives if used for at least 6 months)- prior to enrollment in the study, or abstinence. * have at least 20 inflammatory (papules and pustules) and 25 non-inflammatory (open and closed comedones) lesions with a maximum of 2 nodulocystic lesions on the face (per fda letter 8.21.07). * global severity score from 2-4 * able to refrain from the use of all other topical acne medications or antibiotics during the treatment period. * considered reliable and capable of understanding their responsibility and role in the study. exclusion criteria a subject will be eligible to participate if they meet none of the following exclusion criteria: * subjects with active cystic acne as evidenced by more than 2 facial nodules. * more than 40 papules and/or pustules (inflammatory lesions) * more than 60 open and or closed comedones/milia (non-inflammatory lesions) * overall severity grade of less than 2 or greater than 4, * history of allergy or hypersensitivity to tretinoin. * significant history or clinical evidence of auto-immune, cardiovascular, gastrointestinal, hematological, hepatic, neurological, pancreatic, or renal disease * use of systemic retinoid treatment within six months prior to study initiation. * oral contraceptives should not be started or changed within 3 months prior to study initiation or planned to change during the study. * pregnant or breast-feeding. * participation in a clinical study for acne within 4 months preceding study initiation.
a trial of capecitabine (xeloda), oxaliplatin and irinotecan in combination with bevacizumab in 1st line treatment of metastatic colorectal cancer

Conditions: Metastatic Colorectal Cancer

Summary: a phase i-ii trial of capecitabine (xeloda), oxaliplatin and irinotecan in combination with bevacizumab in 1st line treatment of metastatic colorectal cancer

a phase i-ii trial of capecitabine (xeloda), oxaliplatin and irinotecan in combination with bevacizumab in 1st line treatment of metastatic colorectal cancer

Eligibility criteria:
inclusion criteria: * patients with diagnosed metastatic colorectal cancer exclusion criteria: * patients with diagnosis other than metastatic colorectal cancer

Keywords: metastatic colorectal cancer
efficacy and safety of lornoxicam in patients with acute coronary syndrome

Conditions: Acute Coronary Syndrome

Summary: the purpose of this study is to determine whether nonsteroidal antiinflammatory drug lornoxicam in combination with low dose aspirin (100mg/day) is effective and safe in patients with acute coronary syndrome without persistent st-segment elevation.

nonsteroidal antiinflammatory drugs (nsaids) are the most frequently prescribed drugs in the world. there are a lot of controversial information published during recent years about nsaid cardiosafety. it is still unclear do nsaids develop cardioprotective or cardiotoxic effects in acute and chronic heart disease patients. aim of the study was to investigate safety and efficacy of lornoxicam, nonselective cox-inhibitor, in patients with acute coronary syndrome without st-segment elevation (nsteacs) and to evaluate the influence of lornoxicam on c-reactive protein (crp) and il-6, il-10 levels.

Eligibility criteria:
inclusion criteria: 1. unstable angina verified during first 48 hours after admitting to the hospital or 2. acute miocardial infarction without st-segment elevation verified during first 48 hours after admitting to the hospital exclusion criteria: 1. high risk of bleeding of any location 2. any kind of acute and active inflammatory process (excluding acute coronary syndrome) 3. aspirin or nsaid intolerability 4. no informed consent 5. acute peptic stomach or duodenum ulcer 6. acute or chronic renal failure (serum creatinin \>300 mmol/l) 7. acute cerebrovascular bleeding

Keywords: acs acute coronary syndrome nsaid lornoxicam xefocam
discovering patterns in experiences of patients in esophageal cancer clinical research

Conditions: Esophageal Cancer

Summary: participation in clinical trials usually favors a particular demographic group. but there is limited research available to explain what study attributes affect the completion of these specific demographic groups. this study will investigate the safety and efficacy of esophageal cancer treatments. the focus will be on tracking the rates of completion and withdrawal among these individuals. it will also try to analyze data from the perspective of different demographic groups to check for recurring trends which might yield insights for the sake of future esophageal cancer research.


Eligibility criteria:
inclusion criteria: * patient is at least 18 years of age * diagnosis of esophageal cancer * ability to understand a written informed consent document, and the willingness to sign it. exclusion criteria: * women of childbearing potential without a negative pregnancy test; or women who are lactating. * has a serious medical or psychiatric illness likely to interfere with participation in this clinical study. * inability to perform regular electronic reporting

Keywords: esophageal cancer